Fulltext

A novel germline mutation of PDGFR-β might be associated with clinical response of colorectal cancer to regorafenib

Rechsteiner, M. ; Wild, P. ; Kiessling, M. K. ; Bohnert, A. ; Zhong, Q. ; Stahel, R. A. ; Moch, H. ; Curioni-Fontecedro, A.

In: Annals of Oncology, 2015, vol. 26, no. 1, p. 246-248

Zum persönliche Liste hinzufügen
    Titel
    • A novel germline mutation of PDGFR-β might be associated with clinical response of colorectal cancer to regorafenib
    Autor
    • Rechsteiner, M.. Institute of Surgical Pathology
    • Wild, P.. Institute of Surgical Pathology
    • Kiessling, M. K.. Department of Oncology, University Hospital Zurich, Zurich, Switzerland
    • Bohnert, A.. Institute of Surgical Pathology
    • Zhong, Q.. Institute of Surgical Pathology
    • Stahel, R. A.. Department of Oncology, University Hospital Zurich, Zurich, Switzerland
    • Moch, H.. Institute of Surgical Pathology
    • Curioni-Fontecedro, A.. Department of Oncology, University Hospital Zurich, Zurich, Switzerland
    Dokumententyp
    • Postprint
    Sprache
    • Englisch
    Veröffentlicht in
    • Annals of Oncology, 2015, vol. 26, no. 1, p. 246-248. Oxford University Press
    Andere elektronische Ausgabe
    Klassifikation
    • Gesundheit
    OAI-PMH-ID
    • oai:doc.rero.ch:300944
    Summary
    This is the first description of a germline mutation of the PDGFR-β gene, that correlates with response to regorafenib in a patient with metastatic colorectal cancer